相关实验视频
Updated: Jul 18, 2025

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
血管性肝脏疾病背后的分子机制:专注于血栓形成
Lucia Giuli1, Maria Pallozzi1, Giulia Venturini1
1Hepatology Unit, CEMAD Centro Malattie Dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, 00168 Rome, Italy.
血管性肝脏疾病 (VLDs) 涉及肝脏静脉和鼻腔,导致门脉高血压和纤维化. 了解VLD的分子机制可能会揭示抗凝药作为关键的治疗策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 血管生物学 血管生物学
- 血栓形成的原因之一是血栓形成.
背景情况:
- 血管性肝脏疾病 (VLDs) 在肝硬化和非肝硬化患者中影响肝血管.
- VLD通常涉及门/肝静脉和鼻,导致门高血压和纤维化.
- 许多VLDs表现出一种前体质的状态,不完全理解病原体.
研究的目的:
- 分析关于VLDs分子机制的当前知识.
- 探索凝血失衡在肝脏疾病和纤维生成中的作用.
- 评估抗凝药作为VLDs的潜在治疗策略.
主要方法:
- 对有关血管性肝脏疾病的现有文献的综述.
- 对VLD病原体的分子机制的分析.
- 研究凝血与肝脏纤维化之间的联系.
主要成果:
- VLDs 破坏肝脏平衡,导致门高血压和纤维化.
- 在VLD中,原血栓表型很常见,其机制超出了Virchow的三位一体.
- 凝血失衡越来越被认为是肝脏纤维化的一个驱动因素.
结论:
- 对VLD分子机制的进一步研究至关重要.
- 抗凝药在预防肝脏并发症和改善患者的治疗结果方面表现有前途.
- 了解VLD为肝脏疾病提供了新的治疗途径.
更多相关视频
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Overview of the Vascular System
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...